AIBOTICS, INC. Files Q2 2025 10-Q Report

Ticker: AIBT · Form: 10-Q · Filed: Aug 19, 2025 · CIK: 1763329

Aibotics, INC. 10-Q Filing Summary
FieldDetail
CompanyAibotics, INC. (AIBT)
Form Type10-Q
Filed DateAug 19, 2025
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $350,000, $0, $498
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, company-information

TL;DR

AIBOTICS, INC. filed their Q2 2025 10-Q. All good.

AI Summary

AIBOTICS, INC. filed its quarterly report for the period ending June 30, 2025. The company, formerly known as Mycotopia Therapies, Inc. and 20/20 Global, Inc., is involved in the medicinal chemicals & botanical products sector. Their principal business address is in Heyburn, ID.

Why It Matters

This filing provides investors with an update on AIBOTICS, INC.'s financial performance and operational status for the second quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new information.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of AIBOTICS, INC.?

AIBOTICS, INC. is classified under MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833].

When was the company formerly known as Mycotopia Therapies, Inc.?

The name change from Mycotopia Therapies, Inc. to AIBOTICS, INC. occurred on 20210519.

What is the state of incorporation for AIBOTICS, INC.?

AIBOTICS, INC. is incorporated in Nevada (NV).

What is the fiscal year end for AIBOTICS, INC.?

The fiscal year end for AIBOTICS, INC. is December 31 (1231).

What is the business address of AIBOTICS, INC.?

The business address is 480 22ND STREET, HEYBURN, ID 83336.

Filing Stats: 4,535 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2025-08-19 15:51:48

Key Financial Figures

Filing Documents

—Financial Information

Part I—Financial Information 1

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 202 4 4 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficit for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited) 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 20 4

Controls and Procedures

Controls and Procedures 20

—Other Information

Part II—Other Information 6 Exhibits 21

–FINANCIAL INFORMATION

PART I–FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS AIBOTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (unaudited) ASSETS CURRENT ASSETS: Cash $ 242,179 $ 185,097 Total Current Assets 242,179 185,097 NON-CURRENT ASSETS: Intangible assets, net 943,431 1,271,898 TOTAL ASSETS $ 1,185,610 $ 1,456,995 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable and accrued expenses $ 474,076 $ 283,341 Accrued interest 417,360 399,822 Accrued expenses – related party 958,000 864,000 Convertible note payable, net of debt discount 1,351,884 1,100,000 Notes payable – related party 165,000 165,000 Shares to be issued 2,027,600 2,039,600 TOTAL LIABILITIES 5,393,920 4,851,763 Commitments and contingencies (Note 9 – Commitments and Contingencies) - - MEZZANINE EQUITY Series B Preferred stock, $ 0.001 par value; 1,500,000 shares authorized at June 30, 2025 and December 31, 2024; 200 shares issued and outstanding as of June 30, 2025 and December 31, 2024; liquidation preference of $ 0 as of June 30, 2025 and December 31, 2024 200 200 STOCKHOLDERS' DEFICIT Preferred stock, 5,000,000 shares authorized: Series A Preferred Stock, $ 0.001 par value, 0 shares authorized at June 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively - - Common stock, $ 0.001 par value; 467,000,000 shares authorized at June 30, 2025 and December 31, 2024; 51,625,089 and 39,990,903 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 51,625 39,991 Additional paid in capital 7,626,667 7,374,297 Accumulated deficit ( 11,886,802 ) ( 10,809,256 ) TOTAL STOCKHOLDERS' DEFICIT ( 4,208,310 ) ( 3,394,768 ) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT $ 1,185,610 $ 1,456,995 The accompanying notes are an integral part of these con

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing